home · filing · 0001213900-22-060406
8-K filed September 30, 2022, 7:59 PM ET
ticker SILO
CIK 0001514183
other material
confidence high
sentiment positive
materiality 0.70
Silo Pharma closes $5.75M public offering at $5/share, uplists to Nasdaq; appoints new CFO and director
Silo Pharma, Inc.
Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.
Common stock began trading on Nasdaq Capital Market under ticker SILO on September 27, 2022.
CFO Eric Weisblum resigned; remains CEO and President. Daniel Ryweck appointed CFO with $42,000 annual base salary.
Board appointed Dr. Jeff Pavell as director and chair of nominating and corporate governance committee.
Proceeds to fund product development, marketing, working capital, and potential acquisitions.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Daniel Ryweck
Chief Financial Officer
Effective 2022-09-27
Filed September 30, 2022, 7:59 PM ET
On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company
Departed
Eric Weisblum
Chief Financial Officer
Effective 2022-09-27
Successor Daniel Ryweck
Filed September 30, 2022, 7:59 PM ET
On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.
Appointed
Jeff Pavell
Director
Effective 2022-09-27
Filed September 30, 2022, 7:59 PM ET
On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Ryweck was appointed as Chief Financial Officer at Silo Pharma, Inc..
Action appointed
Role Chief Financial Officer
Exact text from the filing
On September 27, 2022, the Board appointed Daniel Ryweck as Chief Financial Officer of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eric Weisblum resigned as Chief Financial Officer at Silo Pharma, Inc..
Action resigned
Role Chief Financial Officer
Exact text from the filing
On September 27, 2022, Eric Weisblum resigned as our Chief Financial Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeff Pavell was appointed as Director at Silo Pharma, Inc..
Action appointed
Role Director
Exact text from the filing
On September 27, 2022, the Company’s Board of Directors (the “Board”) appointed Jeff Pavell as a member of the Board.
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-22-060406
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.